Triple-negative breast cancer: is there a treatment on the horizon?

Triple-negative breast cancer (TNBC), which accounts for 15–20% of all breast cancers, does not express estrogen receptor (ER) or progesterone receptor (PR) and lacks human epidermal growth factor receptor 2 (HER2) overexpression or amplification. These tumors have a more aggressive phenotype and a...

Descripción completa

Detalles Bibliográficos
Autores principales: Yao, Hui, He, Guangchun, Yan, Shichao, Chen, Chao, Song, Liujiang, Rosol, Thomas J., Deng, Xiyun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5352107/
https://www.ncbi.nlm.nih.gov/pubmed/27765921
http://dx.doi.org/10.18632/oncotarget.12284

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5352107/
https://www.ncbi.nlm.nih.gov/pubmed/27765921
http://dx.doi.org/10.18632/oncotarget.12284

Ejemplares similares